Furthermore, a unilateral decrease in pathogenic CD8+ T cells in circulation and in tissues underscores the synergistic impact of adding ruxolitinib to enhance UCB-Tregs ability to suppress SLE-PBMC (22). Here, CD8A is linked to systemic lupus erythematosus.